BUSINESS WIRE; Tuesday, April 21, 1998
GPI-2A represents the first antisense therapy to undergo clinical testing in Canada. The Company is currently completing a Phase IA clinical trial of GPI-2A in Winnipeg, Manitoba. GPI-2A is a novel antisense compound that is specifically engineered to target the Human Immunodeficiency Virus (HIV) and stop the process of viral replication. It accomplishes this by blocking the sysnthesis of proteins essential for the survival of the virus. Novopharm Biotech believes that GPI-2A will be effective in treating later stages of AIDS, in addition to being safe and effective in combination with currently available theraphies for early stage HIV infection.
The objective of the Phase IB trial is to investigate the tolerability and safety of escalating intravenous and subcutaneous infusions of GPI-2A. The Phase II trial has been designed to evaluate the efficacy, or anti-HIV activity, of GPI-2A in patients that are resistant to currently available HIV therapies or have failed to respond to theraphy with their current regimen.
Dr. Albert Friesen, President of Novopharm Biotech commented "The initial results are very encouraging. I am optimistic about the upcoming clinical trials and look forward to reporting our clinical trial results concerning GPI-2A's efficacy as a potent anti-HIV inhibitor."
Novopharm Biotech's mandate is to become a North American leader in the development and commercialization of innovative and generic biopharmaceutical products. The company is a publicly traded subsidiary of Novopharm Limited one of Canada's largest generic pharmaceutical companies.
This press release contains forward-looking statements which are subject to risks and uncertainties inherent in the process of developing and commercializing human therapeutics. Actual results could differ materially from those projected in this release.
--30--kjs/ix*
CONTACT: Novopharm Biotech Inc., Toronto Stacey Jurchison, 416/291-8888 ext. 5165
Copyright (c) 1998/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
980421
BW980407
Copyright © 1998 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .